phase 3 diabetes trial design
How to Decode Surprising Semaglutide Phase 3 Trial Data
Orforglipron achieved a 1.2% greater A1C drop and a 12% average weight loss versus oral semaglutide, but the headline hinges on trial design choices. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.